Cagrilintide is a long-acting synthetic analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells. It has been studied for its potential role in regulating appetite signaling, gastric emptying, and metabolic balance through interaction with amylin and calcitonin receptors in research settings.

Preclinical and clinical research suggests that cagrilintide may influence satiety pathways within the central nervous system, contributing to reduced food intake and modulation of energy regulation in experimental models. These mechanisms are believed to underlie its observed effects in studies evaluating weight-related signaling, metabolic adaptation, and glycemic balance. Its extended duration of action has been explored for sustained receptor engagement in controlled investigations.

Beyond appetite-related pathways, cagrilintide has also been studied for its potential influence on glucagon regulation, gastric motility, and broader neuroendocrine signaling networks. Ongoing research continues to evaluate its impact on metabolic homeostasis, energy balance, and hormonal regulatory processes.